Author Information
Anne Vincent-Salomon is affiliated with Inserm U934, the department of diagnostic and theranostic medicine, pathology service at Institut Curie, and the Université Paris Sciences Lettres, located at 26, rue d'Ulm, 75005 Paris, France.Research Contributions
Anne Vincent-Salomon has made significant contributions to the field of cancer research, particularly focusing on breast cancer, its molecular characteristics, and treatment responses. In 2022, she published several influential papers, including studies on the survival outcomes of neoadjuvant letrozole and palbociclib versus third-generation chemotherapy for high-risk estrogen receptor-positive HER2-negative breast cancer, the molecular heterogeneity of E-Cadherin expression in invasive lobular breast cancer, and the correlation between centrosome numbers and aggressivity in ovarian cancer. Her work also extends to the development of AI-based solutions for cancer diagnosis, as well as the prediction of treatment responses in triple-negative breast cancer using neural networks. Additionally, she has explored the role of Kindlin-1 in modulating the EGFR pathway and predicting sensitivity to EGFR inhibitors, the value of loss of heterozygosity in BRCA1 variant classification, and the infiltration of innate lymphoid cells in metastatic breast cancer lymph nodes. Her diverse and impactful research underscores her expertise and dedication to advancing cancer diagnostics and treatment.Aliases
Anne Vincent-Salomon is known by several aliases including Anne Vincent-salomon, Anne Vincent‐salomon, A. Vincent-salomon, A Vincent-salomon, and A Vincent‐salomon.Publication and Citation Metrics
| Metric |
Value |
| Citation Count |
36,163 |
| h-index |
88 |
| Paper Count |
595 |
